By driving the circuit (Figure 3), TF hypercoagulability is readily involved in an array of metabolic syndromes (e.g., atherosclerosis, hypertension, diabetes II, and obesity) and other clinical manifestations (e.g., cancers, antiphospholipid syndrome (APS), and fetal loss). This evidence concerns the gene TF and antiphospholipid syndrome.